The impact of donor full‐length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT

An, Kang; Li, Benshang; Luo, Chwan Yau; Wang, Jianmin; Luo, Chengjuan; Chen, Jing

doi:10.1111/petr.13728

Cited by 3 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated that patients with KIR2DS4 positive donors had a higher incidence of graft versus host disease (GVHD) after HSCT. KIR2DS4 expression level may serve as a good predictor of GVHD occurrence after transplantation [30,31]. Studies have found that APOBEC3G had signi cant carcinogenic activity and was highly expressed in a variety of tumors.…”

Section: Discussionmentioning

confidence: 99%

The potential novel immune-related prognostic factors for acute myeloid leukemia

Zheng

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The pathological progression in acute myeloid leukemia (AML) was significantly affected by the immune microenvironment of bone marrow, where the immune-related genes (IRGs) and immune cells are involved in the prognosis of the disease. Studying immune-related components provide new ideas for treatment. Methods The transcriptome data and clinical information of 151 TCGA-LAML and 337 GTEx-whole-blood cohorts were downloaded from the UCSC Xena database. The IRGs were obtained from ImmPort database. Differentially expressed IRGs (DEIGs) were obtained from differentially expressed genes (DEGs). A prognostic model was constructed by COX regression analysis and verified by Kaplan-Meier (K-M) and receiver operating characteristic (ROC) curves in the training and validation cohorts (GEO37642 cohort). The relationship between gene expression level and prognosis was analyzed by K-M method. The independent prognostic factors were screened by univariate and multivariate Cox regression analysis. Relative immune cell composition of AML and healthy samples was calculated using the CIBERSORT algorithm. Results Enrichment analysis revealed that the immune cells and immune-related biology functions participated in AML progression. A prognostic model containing eight genes was constructed. In the training and validation cohorts, the survival rate of the low-risk group was significantly higher than that of the high-risk group. The area under the curve (AUC) values of ROC curves were ≥ 0.7. Among the model, high expression of CANX (P = 0.012), CLEC11A (P = 0.016), and TRH (P = 1.256E-04) was associated with a higher survival rate, while high expression of IL3RA (P = 0.038), KIR2DS4 (P = 0.016), APOBEC3G (P = 1.426E-04), and CKLF (P = 0.015) was associated with lower survival rate. The CANX expression level may affect the sensitivity of some drugs. Age, karyotype, and risk score are independent prognostic factors for AML. The differential level of 17 immune cells was observed between the AML and healthy samples. The levels of Macrophages M1, T cells follicular helper, and T cells CD8 were positively correlated with survival rate. Discussions The prognostic model may be helpful in predicting patient outcomes and 7 IRGs and 3 immune cells may be potential biomarkers and immunotherapy targets for AML in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

The potential novel immune-related prognostic factors for acute myeloid leukemia

Zheng

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell Transplantation

Gowdavally

Tsamadou

Platzbecker

et al. 2023

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

NK cell defects: implication in acute myeloid leukemia

2023

View full text Add to dashboard Cite

Acute Myeloid Leukemia (AML) is a complex disease with rapid progression and poor/unsatisfactory outcomes. In the past few years, the focus has been on developing newer therapies for AML; however, relapse remains a significant problem. Natural Killer cells have strong anti-tumor potential against AML. This NK-mediated cytotoxicity is often restricted by cellular defects caused by disease-associated mechanisms, which can lead to disease progression. A stark feature of AML is the low/no expression of the cognate HLA ligands for the activating KIR receptors, due to which these tumor cells evade NK-mediated lysis. Recently, different Natural Killer cell therapies have been implicated in treating AML, such as the adoptive NK cell transfer, Chimeric antigen receptor-modified NK (CAR-NK) cell therapy, antibodies, cytokine, and drug treatment. However, the data available is scarce, and the outcomes vary between different transplant settings and different types of leukemia. Moreover, remission achieved by some of these therapies is only for a short time. In this mini-review, we will discuss the role of NK cell defects in AML progression, particularly the expression of different cell surface markers, the available NK cell therapies, and the results from various preclinical and clinical trials.

show abstract

The impact of donor full‐length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT

Cited by 3 publications

References 45 publications

The potential novel immune-related prognostic factors for acute myeloid leukemia

The potential novel immune-related prognostic factors for acute myeloid leukemia

KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell Transplantation

NK cell defects: implication in acute myeloid leukemia

Contact Info

Product

Resources

About